|
DE19624659A1
(de)
|
1996-06-20 |
1998-01-08 |
Klinge Co Chem Pharm Fab |
Neue Pyridylalken- und Pyridylalkinsäureamide
|
|
US6451816B1
(en)
|
1997-06-20 |
2002-09-17 |
Klinge Pharma Gmbh |
Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
|
|
JPH10338658A
(ja)
*
|
1997-04-08 |
1998-12-22 |
Hoechst Marion Roussel Kk |
レチノイド作用調節剤
|
|
DE19756235A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
|
|
DE19756261A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
|
|
DE19756212A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
US6903118B1
(en)
|
1997-12-17 |
2005-06-07 |
Klinge Pharma Gmbh |
Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
|
|
DE19818044A1
(de)
*
|
1998-04-22 |
1999-10-28 |
Klinge Co Chem Pharm Fab |
Verwendung von Vitamin-PP-Verbindungen
|
|
EP1112073A4
(en)
*
|
1998-08-12 |
2002-10-25 |
Smithkline Beecham Corp |
CALCILYTIC COMPOUNDS
|
|
DE19908483A1
(de)
*
|
1999-02-26 |
2000-10-05 |
Klinge Co Chem Pharm Fab |
Inhibitoren der zellulären Niacinamidmononucleotid-Bildung
|
|
EP1031564A1
(en)
*
|
1999-02-26 |
2000-08-30 |
Klinge Pharma GmbH |
Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
|
|
JP2004507465A
(ja)
|
2000-08-11 |
2004-03-11 |
ワイス |
エストロゲン受容体陽性癌腫の治療方法
|
|
EP1324990B1
(en)
|
2000-09-29 |
2014-10-29 |
Glaxo Group Limited |
Morpholin-acetamide derivatives for the treatment of inflammatory diseases
|
|
EP1348434A1
(en)
*
|
2002-03-27 |
2003-10-01 |
Fujisawa Deutschland GmbH |
Use of pyridyl amides as inhibitors of angiogenesis
|
|
GB0207445D0
(en)
*
|
2002-03-28 |
2002-05-08 |
Glaxo Group Ltd |
Novel compounds
|
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
|
EA200701745A1
(ru)
|
2005-03-17 |
2008-06-30 |
Пфайзер, Инк. |
Циклопропанкарбоксамидные производные
|
|
PE20071159A1
(es)
|
2005-10-31 |
2007-11-30 |
Schering Corp |
Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
|
|
US8067457B2
(en)
|
2005-11-01 |
2011-11-29 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of CCR2
|
|
WO2007053499A2
(en)
|
2005-11-01 |
2007-05-10 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of ccr2
|
|
HUP0600809A3
(en)
*
|
2006-10-27 |
2008-09-29 |
Richter Gedeon Nyrt |
New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
|
|
EP2098231A1
(en)
|
2008-03-05 |
2009-09-09 |
Topotarget Switzerland SA |
Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
|
|
WO2009156421A1
(en)
|
2008-06-24 |
2009-12-30 |
Topotarget A/S |
Squaric acid derivatives as inhibitors of the nicotinamide
|
|
RU2011111728A
(ru)
|
2008-08-29 |
2012-10-10 |
Топотаргет А/С (Dk) |
Новые производные мочевины и тиомочевины
|
|
CA2768338A1
(en)
|
2009-07-17 |
2011-01-20 |
Topotarget A/S |
Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
|
|
WO2011121055A1
(en)
|
2010-03-31 |
2011-10-06 |
Topotarget A/S |
Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
|
|
CN103270023B
(zh)
|
2010-09-03 |
2016-11-02 |
福马Tm有限责任公司 |
作为用于治疗疾病诸如癌症的nampt 抑制剂的4-{[(吡啶-3-基-甲基)氨基羰基]氨基}苯-砜衍生物
|
|
AR082886A1
(es)
|
2010-09-03 |
2013-01-16 |
Forma Therapeutics Inc |
Compuestos y composiciones farmaceuticas que los contienen
|
|
EP2611804A1
(en)
|
2010-09-03 |
2013-07-10 |
Forma TM, LLC. |
Novel compounds and compositions for the inhibition of nampt
|
|
CN103189356B
(zh)
*
|
2010-09-29 |
2015-11-25 |
英特维特国际股份有限公司 |
N-杂芳基化合物
|
|
MX2013005479A
(es)
|
2010-11-15 |
2013-06-12 |
Abbvie Inc |
Inhibidores de nampt.
|
|
AU2011329233A1
(en)
|
2010-11-15 |
2013-05-23 |
Abbvie Deutschland Gmbh & Co Kg |
NAMPT and ROCK inhibitors
|
|
RU2616612C2
(ru)
|
2011-05-04 |
2017-04-18 |
ФОРМА ТиЭм, ЭлЭлСИ |
Новые соединения и композиции для ингибирования nampt
|
|
MX347459B
(es)
|
2011-05-09 |
2017-04-26 |
Forma Tm Llc |
Nuevos compuestos y composiciones para la inhibición de nampt.
|
|
AR091023A1
(es)
|
2012-05-11 |
2014-12-30 |
Abbvie Inc |
Inhibidores del nampt
|
|
PE20150224A1
(es)
|
2012-05-11 |
2015-03-08 |
Abbvie Inc |
Inhibidores del nampt
|
|
CN104684906B
(zh)
|
2012-05-11 |
2017-06-09 |
艾伯维公司 |
Nampt抑制剂
|
|
MX2014013758A
(es)
|
2012-05-11 |
2015-02-05 |
Abbvie Inc |
Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
|
|
HK1215579A1
(zh)
|
2012-11-29 |
2016-09-02 |
Karyopharm Therapeutics, Inc. |
被取代的2，3-二氫苯並呋喃基化合物和其用途
|
|
DK3016946T3
(da)
|
2013-07-03 |
2023-01-09 |
Karyopharm Therapeutics Inc |
Substituerede benzofuranyl- og benzoxazolylforbindelser og anvendelser deraf
|
|
US9994558B2
(en)
|
2013-09-20 |
2018-06-12 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and methods of using same
|
|
WO2017031323A1
(en)
|
2015-08-18 |
2017-02-23 |
Karyopharm Therapeutics Inc. |
(s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
|
|
US10858347B2
(en)
|
2015-12-31 |
2020-12-08 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and uses thereof
|
|
CA3039589A1
(en)
|
2016-10-18 |
2018-04-26 |
Seattle Genetics, Inc. |
Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
|
|
WO2018086703A1
(en)
|
2016-11-11 |
2018-05-17 |
Bayer Pharma Aktiengesellschaft |
Dihydropyridazinones substituted with phenylureas
|
|
CA3060206A1
(en)
|
2017-04-27 |
2018-11-01 |
Seattle Genetics, Inc. |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
|
EP3746079A1
(en)
|
2018-01-31 |
2020-12-09 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
US12522587B2
(en)
|
2018-05-04 |
2026-01-13 |
Remedy Plan, Inc. |
Cancer treatments targeting cancer stem cells
|
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
EP4055008A1
(en)
|
2019-11-06 |
2022-09-14 |
Remedy Plan, Inc. |
Cancer treatments targeting cancer stem cells
|
|
JP2024518089A
(ja)
|
2021-05-13 |
2024-04-24 |
リメディー プラン，インコーポレーテッド |
Ｎａｍｐｔ阻害剤とその使用
|